STOCKSCOPE

Streamplay Studio (ASX:SP8): 640,000 Game Installs and a Cash-Generating Business. Could This Small-Cap Be Turning a Corner?

Danny Aad

Danny Aad

Technology & Biotechnology Specialist | StockScope

Published:26 Oct 2026
Streamplay Studio (ASX:SP8): 640,000 Game Installs and a Cash-Generating Business. Could This Small-Cap Be Turning a Corner?

Streamplay Studio is building a global gaming business, but its latest numbers suggest the opportunity extends beyond launching new titles. Revenue surged in FY26, operating cash flow turned positive and its mobile publishing subsidiary, Noodlecake Studios, delivered another encouraging commercial milestone. With the shares trading around A$0.007 in early October, we think the key question is whether growing game audiences can translate into sustainable profits.

The numbers worth watching

  • Revenue: A$13.28m in FY26, up 144% year on year.
  • EBITDA: Approximately A$1.2m to A$1.32m, depending on the reported results measure.
  • Operating cash flow: A$2.29m positive, against a A$1.08m outflow in FY25.
  • Cash reserves: A$5.77m at 30 June 2026.
  • Share price: Around A$0.007 in early October, below its 2026 starting level of approximately A$0.010.

A growing publishing portfolio is gaining traction

The latest development is particularly encouraging: on 20 October, Streamplay reported that Flick Shot Rogues had reached 640,000 mobile installs in its first month. Its subsidiary Noodlecake also secured new publishing agreements, expanded into Latin America and saw multiple games selected for Google Play Pass. Meanwhile, Yes, Your Grace 2 launched on Apple and Google storefronts in October, adding another opportunity to monetise its catalogue.

The business model matters. Noodlecake publishes games developed by independent studios, helping creators reach audiences across mobile, PC and console platforms. Streamplay can participate in a title's commercial success without developing every game internally, although publishing advances, marketing costs and revenue-sharing arrangements influence the returns.

Cash flow changes the investment equation

Streamplay's FY26 performance represents a meaningful improvement. Customer receipts reached A$9.55m, compared with A$3.34m a year earlier, while operating cash flow swung from negative to positive. That gives management greater flexibility to fund publishing opportunities and develop its portfolio.

However, the company still recorded a net loss of A$2.37m. Depreciation and amortisation, including costs associated with acquired assets, remain important considerations. Cash also declined from A$7.73m to A$5.77m during FY26, reflecting substantial investment in intangible assets and acquisitions. Continued positive operating cash flow will therefore be essential.

Could the valuation be overlooking the opportunity?

At approximately A$0.007 a share, Streamplay's market capitalisation was around A$9m to A$10m based on its reported share count. That compares with FY26 revenue of A$13.28m. On this historical comparison, the shares trade at less than one times annual revenue, while positive EBITDA provides an early indication of operating potential.

This is not proof of undervaluation. The business remains loss-making, game performance can be unpredictable, and publishing expenditure must generate attractive returns. Nevertheless, the combination of a relatively modest market capitalisation, cash reserves and a growing catalogue makes further commercial progress worth watching.

Insight: Can mobile success become repeatable cash generation?

We see the strongest opportunity in Streamplay's ability to turn a growing publishing portfolio into a more predictable earnings stream. The 640,000 installs for Flick Shot Rogues provide an encouraging early signal, but downloads alone do not establish commercial success. If new releases sustain engagement, generate meaningful revenue and support further positive operating cash flow, the business could strengthen its financial position. The next test is how effectively audience growth converts into receipts and margins.

The next milestone matters

Streamplay has moved beyond a purely speculative growth story, with FY26 demonstrating revenue expansion and positive operating cash flow. The opportunity now rests on execution: monetising successful titles, controlling publishing costs and maintaining cash generation. We will be watching mobile game performance and the next quarterly cash flow report closely. If those indicators improve together, Streamplay's growth story could become considerably more compelling.

Danny Aad

Danny Aad

(Technology & Biotechnology Specialist | StockScope)

Danny Aad is an experienced technology executive with a distinguished career spanning more than three decades, including senior leadership positions as Chief Technology Officer (CTO) across the technology and biotechnology sectors. With extensive expertise in technology strategy, digital innovation and the evolving biotechnology landscape, Danny brings a wealth of industry knowledge and technical insight to his analysis of emerging technologies, corporate developments and investment opportunities.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet
Mining
Mining

Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet

Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...

Alison ElzayedAlison Elzayed•
Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?
Biotech & Health
Biotech & Health

Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...

Danny AadDanny Aad•
Loading more stories...